Montreal Gazette
🏢 Postmedia
📍 QC
May 13, 2026
· 1 min read
AI Analyzed
○ Unverifiable
View full audit trail →
OrganaBio Acquires Excellos Operating Assets, Establishing a Coast-to-Coast Cell Therapy Contract Testing, Development and Manufacturing Organization
Original article ↗ 🔒 Paywalled source — limited preview availableB.I.A.S. ANALYSIS
CENTER
LEFTCENTERRIGHT
Signal breakdown
Heuristic (v1/v3)
0.00 · CENTER-RIGHT
ML v2 (DistilBERT)
0.000 · CENTER
Ensemble
0.000 · CENTER
🏦 Source Intelligence
Rolling outlet bias
CENTER
avg -0.054
2,788 articles tracked
7-day bias trend
LcenterR
V.E.R.I.F.Y. has fact-checked this article.
Subscribe to see claim-by-claim verdicts and reasoning.
Subscribe to see claim-by-claim verdicts and reasoning.
Article Excerpt
New organization leverages manufacturing, PBMC isolation, and cryopreservation services across multiple facilities, supporting cell therapy programs from preclinical through commercial supply Core Excellos team retained; existing customer programs to continue without interruption MIAMI — OrganaBio, LLC (“OrganaBio”), a manufacturer of GMP cells and blood products and provider of cell isolation and cryopreservation services, has acquired...
Read full article at Montreal Gazette ↗
How we scored this article
WTF uses a two-tier system: every article gets a heuristic bias score from keyword analysis, and priority articles (high overlap across 3+ outlets or strong heuristic signal) get full LLM analysis from B.I.A.S. and V.E.R.I.F.Y.
Analyzed by
B.I.A.S.
V.E.R.I.F.Y.
L.O.C.A.L.
quick v1
Jun 8, 2026